Tildrakizumab in Psoriatic Patients With Current or Past Malignancy: A Real-Life Cohort and Literature Review.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Baniandrés Ofelia, Balaguer Franch Inmaculada, Vilarrasa Rull Eva, Imbernón Moya Adrián, Alonso Pacheco María Luisa, Mateu Puchades Almudena, Hergueta Sánchez Julia Paloma, Mataix Díaz Francisco Javier, Ballano Ruiz Adrián, González Cantero Álvaro, Martínez Lorenzo Elena, Galán Gutiérrez Manuel, Rodríguez Fernández-Freire Lourdes, Vila Payeras Aina, Muñoz Santos Carlos, Hernández Bel Pablo, Hernández Ostiz Sergio, Pujol Montcusí Josep, Álvarez Salafranca Marcial, Coto Segura Pablo, Martínez Pallas Isabel, Azón Masoliver Antoni, Martínez Manchón Teresa, Delgado Mucientes Carmen, Schneller-Pavelescu Apetrei Constantin Luca, Ballester Martínez Asunción, Monte Serrano Juan, Pindado Ortega Cristina, Reguero Del Cura Leandra, López Barragán Irene, Chavarría Mur Eva, González Olivares Mónica, de la Cueva Dobao Pablo
Аннотация
OBJECTIVES: To assess the efficacy and safety of tildrakizumab in a cohort of patients with moderate-to-severe psoriasis and a previous or current history of neoplasia.
METHODS: We conducted a retrospective, observational, multicentre study across 27 Spanish dermatology departments. All patients had moderate-to-severe plaque psoriasis and a prior history of an active neoplasia at the time of initiating tildrakizumab treatment.
RESULTS: Forty-eight patients with a mean follow-up period of 50 weeks after initiation of tildrakizumab were included. At Week 24, 82.4% of evaluable patients achieved a Psoriasis Area and Severity Index (PASI) score < 3. By Week 48, 80.0% achieved PASI < 1 and 50.0% reached PASI 0. Twelve patients (25%) began treatment within one year of cancer diagnosis, and four patients started tildrakizumab prior to cancer detection and did not stop treatment. Of the remaining 32, they started tildrakizumab an average of 4.95 years after the cancer diagnosis. Seven patients had active neoplasia at baseline. Overall, 95.8% of the patients did not experience recurrence or worsening of the neoplasia. No adverse events related to tildrakizumab were reported. The cancer state was not considered affected by the psoriasis therapy in any of the cases.
CONCLUSION: The treatment of moderate to severe psoriasis with tildrakizumab was an effective option, with a safe profile in patients with a history of cancer.